The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | Predictors of unsustained MRD negativity in multiple myeloma
In this video, Mattia D’Agostino, MD, University of Turin, European Myeloma Network, Turin, Italy, shares some insights into the importance of measurable residual disease (MRD) as a prognostic tool in multiple myeloma. Dr D’Agostino then highlights predictors of unsustained MRD negativity observed in patients enrolled in the FORTE trial (NCT02203643), including circulating tumor cells (CTCs) and chromosome 1q abnormalities. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
